Jean-François Emile
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Jean-François Emile has a total of 168 co-authors. Here are the top co-authors by number of shared publications:
- Jean-Baptiste Bachet
Department of Gastroenterology, Pitié-Salpêtrière Hospital—Sorbonne Université, Paris, France
7 shared publications - Geraldine Perkins
Georges Pompidou European Hospital, Paris, France
3 shared publications - Pierre Laurent-Puig
Centre de Recherche des Cordeliers
3 shared publications Séverine Tabone-Eglinger
Team “Ciblage thérapeutique de la cellule tumorale et de son environnement immunitaire”, U 1052, UMR 5286, Centre Léon Bérard, 69373 Lyon Cedex 08, France
3 shared publicationsZofia Hélias-Rodzewicz
Hospital Ambroise Pare, APHP, University Versailles-SQY, Boulogne-Billancourt, France
3 shared publications- Bernard Nordlinger
Ambroise Paré Hospital Boulogne
2 shared publications
Latest Publications
- 20 May 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (15_suppl) , e14540
The anti-tumour immune response after radiofrequency ablation of colorectal cancer.
E14540 Background: Results of radiofrequency ablation (RFA), increasingly used to treat liver tumors, are compromised by local and systemic relapse. Hyperthermia related cancer cells death, release of tumor antigens and expression of danger signals activate a tumor-specific T-cells response. This effect remains ineffective to avoid recurrence. Therefore we propose to combine RFA with an activation of a solid immune antitumor response as curative treatment of a colorectal (CRC) metastatic disease in immunocompetent mouse. Methods: RFA was used to treat a CT26- luc tumor. In two distinct clinical situations, distant macroscopic or microscopic tumors were established as metastases before or at the time of RFA. Immune response was modulated by an injection in situof a thermo-reversible hydrogel loaded by GM-CSF and BCG, targeting dendritic cells. In the group of mice with large far lesions this strategy was combined with immune checkpoint inhibition. The efficiency was assessed on survival, evolution of distant lesions, characterization of lymphocyte infiltration in tumors and systemic immunity through specific TNF- α and IFN-y expression in spleen and draining lymph nodes. Results: The in situ immunogel injection after RFA resulted in a prolonged survival of mice. Regression of distant lesions was related to a strong systemic antitumor immune response and a great improvement of tumor infiltration by specific cytotoxic lymphocytes. In adjuvant situation, the use of immunogel induced a complete cure of microscopic secondary lesions without any treatment. Immune escape of large secondary lesions was reversed by association of RFA-immunogel vaccination with a systemic check point blockade, separately ineffective. Conclusions: Validation of this strategy, combining RFA of liver metastases and activation of a strong immune response controlling the residual disease, could result in a clinical assay including this approach within the standard treatment of CRC. Furthermorethe powerful synergy between RFA-in situ immunomodulation as a starter treatment and checkpoint blockade ineffective alone in CRC or after single RFA, allows reconsidering the use of immune checkpoint inhibitors in metastatic microsatellite stable CRC.
- 20 May 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (15_suppl) , e14540
The anti-tumour immune response after radiofrequency ablation of colorectal cancer.
E14540 Background: Results of radiofrequency ablation (RFA), increasingly used to treat liver tumors, are compromised by local and systemic relapse. Hyperthermia related cancer cells death, release of tumor antigens and expression of danger signals activate a tumor-specific T-cells response. This effect remains ineffective to avoid recurrence. Therefore we propose to combine RFA with an activation of a solid immune antitumor response as curative treatment of a colorectal (CRC) metastatic disease in immunocompetent mouse. Methods: RFA was used to treat a CT26- luc tumor. In two distinct clinical situations, distant macroscopic or microscopic tumors were established as metastases before or at the time of RFA. Immune response was modulated by an injection in situof a thermo-reversible hydrogel loaded by GM-CSF and BCG, targeting dendritic cells. In the group of mice with large far lesions this strategy was combined with immune checkpoint inhibition. The efficiency was assessed on survival, evolution of distant lesions, characterization of lymphocyte infiltration in tumors and systemic immunity through specific TNF- α and IFN-y expression in spleen and draining lymph nodes. Results: The in situ immunogel injection after RFA resulted in a prolonged survival of mice. Regression of distant lesions was related to a strong systemic antitumor immune response and a great improvement of tumor infiltration by specific cytotoxic lymphocytes. In adjuvant situation, the use of immunogel induced a complete cure of microscopic secondary lesions without any treatment. Immune escape of large secondary lesions was reversed by association of RFA-immunogel vaccination with a systemic check point blockade, separately ineffective. Conclusions: Validation of this strategy, combining RFA of liver metastases and activation of a strong immune response controlling the residual disease, could result in a clinical assay including this approach within the standard treatment of CRC. Furthermorethe powerful synergy between RFA-in situ immunomodulation as a starter treatment and checkpoint blockade ineffective alone in CRC or after single RFA, allows reconsidering the use of immune checkpoint inhibitors in metastatic microsatellite stable CRC.
- 20 May 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (15_suppl) , 3515
Association of prognostic value of primary tumor location in stage III colon cancer with RAS and BRAF mutational status.
3515 Background: Recent data suggest that the anatomic site of colon primary tumor may be an important factor in the interpretation of molecular markers with clinical outcome in metastatic colon cancer (CC) patients (pts). We assessed here the prognostic value of primary location in fully resected stage III CC pts and its relationship to MSI, RAS and BRAF mutational status. Methods: Pts enrolled in the PETACC-8 trial were analyzed. We categorized tumor site as located proximal (left-sided) or distal (right-sided) to the splenic flexure. The association between tumor location and disease free survival (DFS), survival after relapse (SAR) and overall survival (OS) were assessed by Cox models and adjusted for clinical and pathological features, MSI, BRAF and RASmutation status. The outcome of pts receiving FOLFOX or FOLFOX and cetuximab in the adjuvant setting were also determined according to tumor site. Results: Among the 1869 pts with full molecular data available, 755 (40%) had a right-sided tumor, 164 (10%) were MSI, 942 (50%) were mutated for RAS and 212 (11%) were mutated for BRAF. Right-sided tumor was not prognostic for DFS in the whole population but was associated to a shorter SAR (HR: 1.54 [1.23 - 1.93], p = 0.001) and OS (HR: 1.25 [1.02 - 1.54], p = 0.03). Same results were observed for MSS and for MSI pts. However, when looking at pts mutated for RAS or BRAF(MUT) and those double wild type (DWT) for those mutations, we found that right-sided tumors, when compared to left-sided tumors, was associated with a worst DFS in DWT patients (HR:1.39[1.01-1.92], p = 0.04) and a better DFS in MUT patients (HR:0.77[0.63-0.95], p = 0.01). These results were found independently of the treatment received and no beneficial effect of cetuximab on DFS or OS was observed in left-sided tumors. Conclusions: In the whole study population of stage III CC pts, though right-sided tumor location influences OS as previously reported, it does not seem to influence DFS but only SAR, when disease becomes metastatic. Interestingly, sidedness seems to influence DFS when splitting the population in MUT or DWT for RAS and BRAF, with a worst DFS for right-sided tumors in DWT and a worst DFS for left-sided tumors in RAS or BRAF mutants. Clinical trial information: 2005-003463-23.
- 20 May 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (15_suppl) , 3515
Association of prognostic value of primary tumor location in stage III colon cancer with RAS and BRAF mutational status.
3515 Background: Recent data suggest that the anatomic site of colon primary tumor may be an important factor in the interpretation of molecular markers with clinical outcome in metastatic colon cancer (CC) patients (pts). We assessed here the prognostic value of primary location in fully resected stage III CC pts and its relationship to MSI, RAS and BRAF mutational status. Methods: Pts enrolled in the PETACC-8 trial were analyzed. We categorized tumor site as located proximal (left-sided) or distal (right-sided) to the splenic flexure. The association between tumor location and disease free survival (DFS), survival after relapse (SAR) and overall survival (OS) were assessed by Cox models and adjusted for clinical and pathological features, MSI, BRAF and RASmutation status. The outcome of pts receiving FOLFOX or FOLFOX and cetuximab in the adjuvant setting were also determined according to tumor site. Results: Among the 1869 pts with full molecular data available, 755 (40%) had a right-sided tumor, 164 (10%) were MSI, 942 (50%) were mutated for RAS and 212 (11%) were mutated for BRAF. Right-sided tumor was not prognostic for DFS in the whole population but was associated to a shorter SAR (HR: 1.54 [1.23 - 1.93], p = 0.001) and OS (HR: 1.25 [1.02 - 1.54], p = 0.03). Same results were observed for MSS and for MSI pts. However, when looking at pts mutated for RAS or BRAF(MUT) and those double wild type (DWT) for those mutations, we found that right-sided tumors, when compared to left-sided tumors, was associated with a worst DFS in DWT patients (HR:1.39[1.01-1.92], p = 0.04) and a better DFS in MUT patients (HR:0.77[0.63-0.95], p = 0.01). These results were found independently of the treatment received and no beneficial effect of cetuximab on DFS or OS was observed in left-sided tumors. Conclusions: In the whole study population of stage III CC pts, though right-sided tumor location influences OS as previously reported, it does not seem to influence DFS but only SAR, when disease becomes metastatic. Interestingly, sidedness seems to influence DFS when splitting the population in MUT or DWT for RAS and BRAF, with a worst DFS for right-sided tumors in DWT and a worst DFS for left-sided tumors in RAS or BRAF mutants. Clinical trial information: 2005-003463-23.
- 1 February 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (4_suppl) , 300
Genomic profiling of ampullary adenocarcinoma (AA): Insights from a comparative analysis of pancreatic and intestinal adenocarcinoma and opportunities for targeted therapies use.
300 Background: Ampullary adenocarcinoma (AA) is a rare entity. AA can originate from either intestinal or pancreaticobiliary ductal epithelium, and patients are often managed as those with pancreaticobiliary carcinomas. The study objectives were the genetic profiling of AA and the identification of specific molecular profiles according to these 2 pathological types. Methods: AA patients included in the AGEO retrospective multicenter cohort who underwent surgical resection of their tumor between 1999 and 2010 were selected. Formalin-fixed, paraffin-embedded (FFPE) archival tissue blocks were collected. Next generation sequencing (NGS) using a 50 gene panel (Ion AmpliSeq Cancer panel) on tumor DNA, and immunohistochemistry (IHC) panel including CK7, CK20, MUC1, MUC2 and CDX2, on tumor sections, were performed. Results: NGS was performed on 101 tumors from 6 hospitals, with 1 technical failure. In total, the most frequent gene mutations were: KRAS (45%), TP53 (40%), APC (15%), PIK3CA (12%), SMAD4 (9%), BRAF (8%), CDKN2A (6%). No mutation was found in 21% of tumors. According to IHC, the most common histological type was intestinal (51%), followed by pancreaticobiliary type (42%) and undetermined (7%). BRAF mutation was significantly associated with intestinal type (8 vs 0, p = 0.017). According to Cosmic database, similarities of molecular profiles exist between AA with intestinal type and colorectal adenocarcinoma, and between AA with pancreaticobiliary type and pancreas adenocarcinoma, respectively. Conclusions: This study shows that AA is a heterogeneous entity and that a large proportion of AA presents a molecular profile that is more similar to that of colorectal adenocarcinoma, compared to pancreatic adenocarcinoma. This important information could be interesting to guide treatment decision in patients with this rare disease.
- 1 February 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (4_suppl) , 300
Genomic profiling of ampullary adenocarcinoma (AA): Insights from a comparative analysis of pancreatic and intestinal adenocarcinoma and opportunities for targeted therapies use.
300 Background: Ampullary adenocarcinoma (AA) is a rare entity. AA can originate from either intestinal or pancreaticobiliary ductal epithelium, and patients are often managed as those with pancreaticobiliary carcinomas. The study objectives were the genetic profiling of AA and the identification of specific molecular profiles according to these 2 pathological types. Methods: AA patients included in the AGEO retrospective multicenter cohort who underwent surgical resection of their tumor between 1999 and 2010 were selected. Formalin-fixed, paraffin-embedded (FFPE) archival tissue blocks were collected. Next generation sequencing (NGS) using a 50 gene panel (Ion AmpliSeq Cancer panel) on tumor DNA, and immunohistochemistry (IHC) panel including CK7, CK20, MUC1, MUC2 and CDX2, on tumor sections, were performed. Results: NGS was performed on 101 tumors from 6 hospitals, with 1 technical failure. In total, the most frequent gene mutations were: KRAS (45%), TP53 (40%), APC (15%), PIK3CA (12%), SMAD4 (9%), BRAF (8%), CDKN2A (6%). No mutation was found in 21% of tumors. According to IHC, the most common histological type was intestinal (51%), followed by pancreaticobiliary type (42%) and undetermined (7%). BRAF mutation was significantly associated with intestinal type (8 vs 0, p = 0.017). According to Cosmic database, similarities of molecular profiles exist between AA with intestinal type and colorectal adenocarcinoma, and between AA with pancreaticobiliary type and pancreas adenocarcinoma, respectively. Conclusions: This study shows that AA is a heterogeneous entity and that a large proportion of AA presents a molecular profile that is more similar to that of colorectal adenocarcinoma, compared to pancreatic adenocarcinoma. This important information could be interesting to guide treatment decision in patients with this rare disease.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 9578
Frequent allelic imbalance in NRAS mutant melanomas.
9578 Background: We recently showed that 19% of BRAF mutant melanomas have an increased mutant allele percentage ( > 60%) (BMC Cancer 2015). This allelic imbalance was mainly related to a polysomy of chromosome 7. We investigated the percentage of NRAS mutant allele in BRAFwild type (WT) melanomas. Methods: We searched for NRAS Q61 mutation by pyrosequencing method in 216 FFPE samples of cutaneous melanomas WT for BRAFV600. FISH was performed with probes specific for NRAS (RP11-245I3) and 1p34.1 (RP11-269F19) on 105 cases NRAS WT (n = 42), or NRAS mutant with equilibrate (E%, n = 43) and high (H%, n = 20) mutant allele percentage. Loss of Heterozygoty (LOH) was evaluated with 8 microsatellite (MS) markers (3 localized near NRAS, 3 at 1p and 2 at 1q) on 17 samples (E% n = 8 or H% n = 9). Pathological data of 73 NRASmutant melanomas, clinical characteristics and survival data of matching patients were analyzed. Results: NRAS mutation was detected in 109 (50.5%) of BRAF WT samples, of which 31 (34%) were H%. Allelic NRAS imbalance was observed in all mutation types: Q61R (n = 22), Q61K (n = 6), Q61L (n = 2) and Q61H (n = 1). Chromosome 1 disomy, disomy with rare polysomic cells and polysomy were observed in 24% (24% WT vs 24% mutant NRAS), in 24% (33% WT vs 18% mutant NRAS) and in 12% (3% WT vs 18% mutant NRAS) of samples, respectively. NRAS amplification and monosomy of chromosome 1 were rare aberrations in both groups (3.4% and 4.6%, respectively). Intra-tumor heterogeneity concerning chromosome 1 was defined as monosomic or polysomic cells (or both) accompanying disomic tumor cells. Heterogeneity was observed in 24% WT and 35% mutant NRAS samples (P < 0.01), and was more frequent in H% than E% mutant NRAS (47% vs 29.7%). MS analysis revealed no LOH in 8 E%, while LOH was present in 9 H% NRAS samples. No differences were observed between E% and H% NRAS mutant melanomas for clinic, histology and survival data. Conclusions: Allelic imbalance is more frequent in NRAS than in BRAF mutant melanomas (34% versus 19% of H%, P < 0.01). Amplification was rare in NRAS, as shown in BRAF mutant melanomas. NRAS mutant melanomas had high intra-tumor heterogeneity. Allelic imbalance of H% NRAS was closely related to LOH.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 9578
Frequent allelic imbalance in NRAS mutant melanomas.
9578 Background: We recently showed that 19% of BRAF mutant melanomas have an increased mutant allele percentage ( > 60%) (BMC Cancer 2015). This allelic imbalance was mainly related to a polysomy of chromosome 7. We investigated the percentage of NRAS mutant allele in BRAFwild type (WT) melanomas. Methods: We searched for NRAS Q61 mutation by pyrosequencing method in 216 FFPE samples of cutaneous melanomas WT for BRAFV600. FISH was performed with probes specific for NRAS (RP11-245I3) and 1p34.1 (RP11-269F19) on 105 cases NRAS WT (n = 42), or NRAS mutant with equilibrate (E%, n = 43) and high (H%, n = 20) mutant allele percentage. Loss of Heterozygoty (LOH) was evaluated with 8 microsatellite (MS) markers (3 localized near NRAS, 3 at 1p and 2 at 1q) on 17 samples (E% n = 8 or H% n = 9). Pathological data of 73 NRASmutant melanomas, clinical characteristics and survival data of matching patients were analyzed. Results: NRAS mutation was detected in 109 (50.5%) of BRAF WT samples, of which 31 (34%) were H%. Allelic NRAS imbalance was observed in all mutation types: Q61R (n = 22), Q61K (n = 6), Q61L (n = 2) and Q61H (n = 1). Chromosome 1 disomy, disomy with rare polysomic cells and polysomy were observed in 24% (24% WT vs 24% mutant NRAS), in 24% (33% WT vs 18% mutant NRAS) and in 12% (3% WT vs 18% mutant NRAS) of samples, respectively. NRAS amplification and monosomy of chromosome 1 were rare aberrations in both groups (3.4% and 4.6%, respectively). Intra-tumor heterogeneity concerning chromosome 1 was defined as monosomic or polysomic cells (or both) accompanying disomic tumor cells. Heterogeneity was observed in 24% WT and 35% mutant NRAS samples (P < 0.01), and was more frequent in H% than E% mutant NRAS (47% vs 29.7%). MS analysis revealed no LOH in 8 E%, while LOH was present in 9 H% NRAS samples. No differences were observed between E% and H% NRAS mutant melanomas for clinic, histology and survival data. Conclusions: Allelic imbalance is more frequent in NRAS than in BRAF mutant melanomas (34% versus 19% of H%, P < 0.01). Amplification was rare in NRAS, as shown in BRAF mutant melanomas. NRAS mutant melanomas had high intra-tumor heterogeneity. Allelic imbalance of H% NRAS was closely related to LOH.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 7069
Recurrent BRAF mutations in bone marrow progenitors of patients with Erdheim-Chester disease.
7069 Background: Erdheim-Chester disease (ECD) and Langerhans cell histiocytosis (LCH) are disorders marked by tissue infiltration with macrophages or dendritic cells. > 80% of ECD and LCH patients have somatic activating mutations in BRAF or other genes involved in the MAP kinase pathway. Up to 20% of ECD patients also have LCH lesions, reported herein as mixed histiocytosis (MH). Although typically considered a disease of tissue infiltrating cells, circulating CD14+ monocytes have been occasionally reported to carry somatic mutations in LCH and ECD patients. We therefore analyzed hematopoetic stem/progenitor cells of adult patients with ECD or MH to identify a cell-of-origin for these disorders. Methods: Blood and/or bone marrow (BM) cells from adult patients with ECD (n = 12) or MH (n = 3) mutated for BRAF were collected and sorted by FACS into different cell fractions. Clonogenic progenitors from sorted BM CD34+ cells were assayed in methylcellulose cultures. BM CD34+ cells were also seeded in liquid culture under conditions allowing their differentiation into myeloid (mDC) or plasmacytoid (pDC) dendritic cells. BRAF mutations were detected by allele specific real time (RT) or picodroplet digital (pDD) polymerase chain reaction (PCR) in the different cell subsets. Results: BRAF mutations were detected in BM CD34+ cells or derived colonies in 7/15 patients, corresponding to 5/12 ECD and 2/3 MH. Among BM CD34-derived colonies or cells, the mutation was detected in CFU-M (n = 3), CFU-G (n = 1), CD14 cells (n = 3), pDC (n = 2), but not in BFU-E nor mDC. In 2/3 patients with ECD, low frequencies of BRAF mutants were detected within CD14+ and CD3+-sorted blood cells. Four patients received vemurafenib. One was on treatment at time of BM sampling and had no mutation in BM cells. The 3 others were no more treated since 3 to 6 months and had evidence of clinical relapse. Two of these later had BRAF mutant BM cells. Conclusions: BRAF mutations can be detected in hematopoietic/stem progenitor cells in patients with ECD and MH. These data suggests that these histiocytoses originate from altered BM progenitors.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 7069
Recurrent BRAF mutations in bone marrow progenitors of patients with Erdheim-Chester disease.
7069 Background: Erdheim-Chester disease (ECD) and Langerhans cell histiocytosis (LCH) are disorders marked by tissue infiltration with macrophages or dendritic cells. > 80% of ECD and LCH patients have somatic activating mutations in BRAF or other genes involved in the MAP kinase pathway. Up to 20% of ECD patients also have LCH lesions, reported herein as mixed histiocytosis (MH). Although typically considered a disease of tissue infiltrating cells, circulating CD14+ monocytes have been occasionally reported to carry somatic mutations in LCH and ECD patients. We therefore analyzed hematopoetic stem/progenitor cells of adult patients with ECD or MH to identify a cell-of-origin for these disorders. Methods: Blood and/or bone marrow (BM) cells from adult patients with ECD (n = 12) or MH (n = 3) mutated for BRAF were collected and sorted by FACS into different cell fractions. Clonogenic progenitors from sorted BM CD34+ cells were assayed in methylcellulose cultures. BM CD34+ cells were also seeded in liquid culture under conditions allowing their differentiation into myeloid (mDC) or plasmacytoid (pDC) dendritic cells. BRAF mutations were detected by allele specific real time (RT) or picodroplet digital (pDD) polymerase chain reaction (PCR) in the different cell subsets. Results: BRAF mutations were detected in BM CD34+ cells or derived colonies in 7/15 patients, corresponding to 5/12 ECD and 2/3 MH. Among BM CD34-derived colonies or cells, the mutation was detected in CFU-M (n = 3), CFU-G (n = 1), CD14 cells (n = 3), pDC (n = 2), but not in BFU-E nor mDC. In 2/3 patients with ECD, low frequencies of BRAF mutants were detected within CD14+ and CD3+-sorted blood cells. Four patients received vemurafenib. One was on treatment at time of BM sampling and had no mutation in BM cells. The 3 others were no more treated since 3 to 6 months and had evidence of clinical relapse. Two of these later had BRAF mutant BM cells. Conclusions: BRAF mutations can be detected in hematopoietic/stem progenitor cells in patients with ECD and MH. These data suggests that these histiocytoses originate from altered BM progenitors.
- 1 February 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (4_suppl) , 622
Hypermethylated circulating DNA detection using picoliter droplet-based PCR in colorectal cancer.
622 Background: Circulating tumor DNA (ctDNA) is thoroughly investigated as a surrogate biomarker of tumor follow-up, in different cancer types, such as colorectal cancer (CRC). Droplet-based digital PCR (ddPCR) is a highly sensitive and also quantitative method for detection of very low amount of ctDNA. Since many different genes can be mutated within a specific tumor type and also wide mutation spectrum can occur within a specific gene, procedures for ctDNA monitoring can be time consuming and need to be improved for a routinely use. To overcome these drawbacks, we characterized the methylation status of 3 genes frequently hypermethylated in CRC to identify universal markers for tumor follow-up. Methods: The characterization of the methylated status of the WIF, NPY and PENK genes in the tumor DNA was performed in 56 CRC of different stages and 45 corresponding plasma samples using droplet-based dPCR, after DNA bisulfite conversion. A two-panels assay (with albumin as a reference) was developed. Methylation level of these 3 genes in tumor tissues was compared to corresponding normal tissues (n = 22) and plasma samples (MetctDNA). To validate, plasma samples of additional 91 patients were analyzed for the presence of ctDNA both by the characterization of KRAS, BRAF, TP53 and PIK3CA mutations (MutctDNA) and of MetctDNA, at various stages of their follow-up, and 9 of them had MetctDNA assessment during treatment follow-up. Results: All tumor samples were positive for WIF1 and/or NPY markers. Hypermethylation of these two genes was significantly higher in tumor tissue compared to normal, independently of the tumor stage (p < 0.0001). MetctDNA could be detected in 75% of metastatic CRC patients and 24% of localized CRC patients (stage 1 to 3). MetctDNA and MutctDNA fractions were strongly correlated (R2 > 0.9, p < 0.0001). During follow-up, MetctDNA levels changes allowed monitoring of tumor evolution in different stages CRC patients. Conclusions: These results indicate that determination of MetctDNA by droplet-based dPCR can reach same efficiency than MutctDNA for ctDNA assessment, using only 2 markers, and thus could be considered as a universal surrogate marker of tumor follow-up in CRC patients.
- 1 February 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (4_suppl) , 622
Hypermethylated circulating DNA detection using picoliter droplet-based PCR in colorectal cancer.
622 Background: Circulating tumor DNA (ctDNA) is thoroughly investigated as a surrogate biomarker of tumor follow-up, in different cancer types, such as colorectal cancer (CRC). Droplet-based digital PCR (ddPCR) is a highly sensitive and also quantitative method for detection of very low amount of ctDNA. Since many different genes can be mutated within a specific tumor type and also wide mutation spectrum can occur within a specific gene, procedures for ctDNA monitoring can be time consuming and need to be improved for a routinely use. To overcome these drawbacks, we characterized the methylation status of 3 genes frequently hypermethylated in CRC to identify universal markers for tumor follow-up. Methods: The characterization of the methylated status of the WIF, NPY and PENK genes in the tumor DNA was performed in 56 CRC of different stages and 45 corresponding plasma samples using droplet-based dPCR, after DNA bisulfite conversion. A two-panels assay (with albumin as a reference) was developed. Methylation level of these 3 genes in tumor tissues was compared to corresponding normal tissues (n = 22) and plasma samples (MetctDNA). To validate, plasma samples of additional 91 patients were analyzed for the presence of ctDNA both by the characterization of KRAS, BRAF, TP53 and PIK3CA mutations (MutctDNA) and of MetctDNA, at various stages of their follow-up, and 9 of them had MetctDNA assessment during treatment follow-up. Results: All tumor samples were positive for WIF1 and/or NPY markers. Hypermethylation of these two genes was significantly higher in tumor tissue compared to normal, independently of the tumor stage (p < 0.0001). MetctDNA could be detected in 75% of metastatic CRC patients and 24% of localized CRC patients (stage 1 to 3). MetctDNA and MutctDNA fractions were strongly correlated (R2 > 0.9, p < 0.0001). During follow-up, MetctDNA levels changes allowed monitoring of tumor evolution in different stages CRC patients. Conclusions: These results indicate that determination of MetctDNA by droplet-based dPCR can reach same efficiency than MutctDNA for ctDNA assessment, using only 2 markers, and thus could be considered as a universal surrogate marker of tumor follow-up in CRC patients.
- 1 February 2013
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 31 (4) , 26
Assessment of HER2 status from an epidemiology study in tumor tissue samples of gastric and gastro-esophageal junction cancer: Results from the french cohort of the HER-EAGLE study.
26 Background: HER2 is an important prognostic and also a predictive biomarker for trastuzumab response in gastric cancer. Therefore, HER2 status should be tested in all gastro-esophageal junction (GEJ) and gastric cancer (GC) patients. ToGA phase III study showed a benefit in overall survival of trastuzumab added to standard chemotherapy in patients with HER2-positive advanced GEJ/GC. The objective of the HER-EAGLE study was to assess the incidence of HER2 positivity in GEJ/GC cancer. Methods: HER-EAGLE was an international epidemiological, non-interventional study assessing HER2 status by IHC/ISH in tumor samples from any stage in patients with GEJ/GC. Samples were obtained by excision or core biopsy and routinely analyzed via validated Ventana or Dako methods and scoring criteria used in ToGA: HER2-positive if IHC 3+ or IHC 2+ (FISH/SISH confirmed; HER2/CEP17 ratio ≥ 2.0); HER2-negative if IHC 0 or IHC 1+ or IHC 2+ if FISH/SISH negative ratio < 2.0. Overall and subgroup estimates calculated with 95% CI. Data from the French cohort are presented. Results: The HER-EAGLE French cohort included 267 patients (68.6% males) from 7 centers (May 2007 to March 2012), with 150 biopsies (56.2%) and 117 excisions (43.8%). Tumor locations were 65.9% stomach and 34.1% GEJ, and adenocarcinoma types were according to Lauren classification: 170 intestinal (63.7%), 72 diffused (27%), 22 mixed (8.2%) and 3 not available (1.1%). HER2 status was: 36 cases IHC 3+ (13.5%), 51 IHC 2+ (19.1%) whereof 18 ISH positive (35.3%), 35 IHC 1+ (13.1%) and 145 IHC 0 (54.3%). Overall HER2 positivity (IHC 3+ or IHC 2+/ISH+) was 20.2%. Heterogeneity for HER2 staining was observed in 81 samples (30.3%). No statistical difference was found according to cancer stage. HER2 positivity was higher in GEJ (31.9%) than in GC (14.2%), p
- 1 February 2013
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 31 (4) , 26
Assessment of HER2 status from an epidemiology study in tumor tissue samples of gastric and gastro-esophageal junction cancer: Results from the french cohort of the HER-EAGLE study.
26 Background: HER2 is an important prognostic and also a predictive biomarker for trastuzumab response in gastric cancer. Therefore, HER2 status should be tested in all gastro-esophageal junction (GEJ) and gastric cancer (GC) patients. ToGA phase III study showed a benefit in overall survival of trastuzumab added to standard chemotherapy in patients with HER2-positive advanced GEJ/GC. The objective of the HER-EAGLE study was to assess the incidence of HER2 positivity in GEJ/GC cancer. Methods: HER-EAGLE was an international epidemiological, non-interventional study assessing HER2 status by IHC/ISH in tumor samples from any stage in patients with GEJ/GC. Samples were obtained by excision or core biopsy and routinely analyzed via validated Ventana or Dako methods and scoring criteria used in ToGA: HER2-positive if IHC 3+ or IHC 2+ (FISH/SISH confirmed; HER2/CEP17 ratio ≥ 2.0); HER2-negative if IHC 0 or IHC 1+ or IHC 2+ if FISH/SISH negative ratio < 2.0. Overall and subgroup estimates calculated with 95% CI. Data from the French cohort are presented. Results: The HER-EAGLE French cohort included 267 patients (68.6% males) from 7 centers (May 2007 to March 2012), with 150 biopsies (56.2%) and 117 excisions (43.8%). Tumor locations were 65.9% stomach and 34.1% GEJ, and adenocarcinoma types were according to Lauren classification: 170 intestinal (63.7%), 72 diffused (27%), 22 mixed (8.2%) and 3 not available (1.1%). HER2 status was: 36 cases IHC 3+ (13.5%), 51 IHC 2+ (19.1%) whereof 18 ISH positive (35.3%), 35 IHC 1+ (13.1%) and 145 IHC 0 (54.3%). Overall HER2 positivity (IHC 3+ or IHC 2+/ISH+) was 20.2%. Heterogeneity for HER2 staining was observed in 81 samples (30.3%). No statistical difference was found according to cancer stage. HER2 positivity was higher in GEJ (31.9%) than in GC (14.2%), p
- 1 January 2013
- Published by Springer Nature
- p. 373-384
L’anatomopathologie à l’ère de la médecine personnalisée : du diagnostic à la théranostique
- 1 January 2013
- Published by Springer Nature
- p. 373-384
L’anatomopathologie à l’ère de la médecine personnalisée : du diagnostic à la théranostique
- 1 December 2012
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 24 (12) , 1430-1437
Colorectal neuroendocrine carcinomas and adenocarcinomas share oncogenic pathways. A clinico-pathologic study of 12 cases
Objective Neuroendocrine carcinomas (NECs) are rare neoplasms with an increasing incidence. Oncogenetic pathways of colorectal NEC are still poorly understood, and no treatment standards are available for these rare tumors. Methods We analyzed retrospectively the clinical records and histology of 12 patients with colorectal NEC. KRAS and BRAF mutations were investigated after the dissection of exoendocrine and neuroendocrine components. ALK alterations and EML4-ALK transcripts were detected by in-situ hybridization and determination of fusion transcripts, respectively. Results At the time of diagnosis, the mean age of the patients was 60 years (40–79) and 10 patients had synchronous metastases. A transient response occurred in two patients and one patient treated with cisplatin–etoposide or fluoropyrimidine–oxaliplatin, respectively. Tumor progression-related death occurred in 11 of 12 patients. Ten tumors contained an exocrine component, accounting for 5–70% of the tumor, and the other two contained an amphicrine component. BRAF/KRAS mutations were found in six of 10 tumors, corresponding to BRAFV600E (n=2) or KRASG12D (n=2), KRASG12V or KRASG13D. DNA was obtained from both exocrine and endocrine components in seven cases, and the BRAF/KRAS status was identical in all cases. Split of the ALK locus was detected in a minority of tumor cells in two of eight cases, but EML4-ALK transcripts were absent. Conclusion The association of an exocrine component in all cases and the similar profile of BRAF/KRAS mutations indicate that colorectal NEC may correspond to a high-grade transformation of colorectal carcinoma. New chemotherapy regimens using targeted therapies should be assessed in these tumors.
- 1 December 2012
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 24 (12) , 1430-1437
Colorectal neuroendocrine carcinomas and adenocarcinomas share oncogenic pathways. A clinico-pathologic study of 12 cases
Objective Neuroendocrine carcinomas (NECs) are rare neoplasms with an increasing incidence. Oncogenetic pathways of colorectal NEC are still poorly understood, and no treatment standards are available for these rare tumors. Methods We analyzed retrospectively the clinical records and histology of 12 patients with colorectal NEC. KRAS and BRAF mutations were investigated after the dissection of exoendocrine and neuroendocrine components. ALK alterations and EML4-ALK transcripts were detected by in-situ hybridization and determination of fusion transcripts, respectively. Results At the time of diagnosis, the mean age of the patients was 60 years (40–79) and 10 patients had synchronous metastases. A transient response occurred in two patients and one patient treated with cisplatin–etoposide or fluoropyrimidine–oxaliplatin, respectively. Tumor progression-related death occurred in 11 of 12 patients. Ten tumors contained an exocrine component, accounting for 5–70% of the tumor, and the other two contained an amphicrine component. BRAF/KRAS mutations were found in six of 10 tumors, corresponding to BRAFV600E (n=2) or KRASG12D (n=2), KRASG12V or KRASG13D. DNA was obtained from both exocrine and endocrine components in seven cases, and the BRAF/KRAS status was identical in all cases. Split of the ALK locus was detected in a minority of tumor cells in two of eight cases, but EML4-ALK transcripts were absent. Conclusion The association of an exocrine component in all cases and the similar profile of BRAF/KRAS mutations indicate that colorectal NEC may correspond to a high-grade transformation of colorectal carcinoma. New chemotherapy regimens using targeted therapies should be assessed in these tumors.
- Open Access
- 13 November 2012
- Published by Springer Nature in Diagnostic Pathology
- Vol. 7 (1) , 156
Linear quantification of lymphoid infiltration of the tumor margin: a reproducible method, developed with colorectal cancer tissues, for assessing a highly variable prognostic factor
Background: Lymphoid infiltration is a prognostic marker in solid tumors, such as colorectal, breast and lung carcinomas. However, lymphoid infiltration is heterogeneous and the reproducibility of quantification based on single counts within a tumor is very low. We aimed to develop a reproducible method for evaluating lymphoid infiltration in tumors. Methods: Virtual slides were obtained from tissue sections from the localized colorectal carcinomas of 117 patients, stained for CD3 and CD45R0. We assessed the variation of lymphoid cell density by automatic counts in 1 mm-wide, 5 μm-long segments of the invasive front, along an axis 4 mm in length running perpendicular to the invasive front of the tumor. Results: We plotted curves of the variation of lymphocyte density across the tumor front. Three distinct patterns emerged from this linear quantification of lymphocyte (LQLI). In pattern 1, there was a high density of lymphocytes within the tumor. In pattern 2, lymphocyte density peaked close to the invasive margin. In pattern 3, lymphocytes were diffusely distributed, at low density. It was possible to classify all the tumors studied, and interobserver reproducibility was excellent (kappa =0.9). By contrast, single counts of CD3+ cells on tissue microarrays were highly variable for a given LQLI pattern, confirming the heterogeneity of lymphoid infiltration within individual tumors. In univariate analysis, all pathologic features (stage, metastatic lymph node ratio (LNR), vascular embolism, perineural invasion), CD3+ cell density, LQLI patterns for CD3+ and CD45R0+ cells) were found to have a significant effect on disease-free survival (DFS). In multivariate analysis, only the LQLI pattern for CD3+ cells (HR: 6.02; 95% CI: 2.74-13.18) and metastatic lymph node ratio (HR: 6.14; 95% CI: 2.32-16.2) were associated with DFS. Conclusion: LQLI is an automated, reproducible method for the assessment of lymphoid infiltration. However, validation of its prognostic value in larger series is required before its introduction into routine practice for prognostic evaluation in patients with colorectal carcinomas. Virtual slides: The virtual slide(s) for this article can be found here:http://www.diagnosticpathology.diagnomx.eu/vs/9861460717895880
- 13 November 2012
- Published by Springer Nature in Diagnostic Pathology
- Vol. 7 (1) , 156
Open AccessLinear quantification of lymphoid infiltration of the tumor margin: a reproducible method, developed with colorectal cancer tissues, for assessing a highly variable prognostic factor
Background: Lymphoid infiltration is a prognostic marker in solid tumors, such as colorectal, breast and lung carcinomas. However, lymphoid infiltration is heterogeneous and the reproducibility of quantification based on single counts within a tumor is very low. We aimed to develop a reproducible method for evaluating lymphoid infiltration in tumors. Methods: Virtual slides were obtained from tissue sections from the localized colorectal carcinomas of 117 patients, stained for CD3 and CD45R0. We assessed the variation of lymphoid cell density by automatic counts in 1 mm-wide, 5 μm-long segments of the invasive front, along an axis 4 mm in length running perpendicular to the invasive front of the tumor. Results: We plotted curves of the variation of lymphocyte density across the tumor front. Three distinct patterns emerged from this linear quantification of lymphocyte (LQLI). In pattern 1, there was a high density of lymphocytes within the tumor. In pattern 2, lymphocyte density peaked close to the invasive margin. In pattern 3, lymphocytes were diffusely distributed, at low density. It was possible to classify all the tumors studied, and interobserver reproducibility was excellent (kappa =0.9). By contrast, single counts of CD3+ cells on tissue microarrays were highly variable for a given LQLI pattern, confirming the heterogeneity of lymphoid infiltration within individual tumors. In univariate analysis, all pathologic features (stage, metastatic lymph node ratio (LNR), vascular embolism, perineural invasion), CD3+ cell density, LQLI patterns for CD3+ and CD45R0+ cells) were found to have a significant effect on disease-free survival (DFS). In multivariate analysis, only the LQLI pattern for CD3+ cells (HR: 6.02; 95% CI: 2.74-13.18) and metastatic lymph node ratio (HR: 6.14; 95% CI: 2.32-16.2) were associated with DFS. Conclusion: LQLI is an automated, reproducible method for the assessment of lymphoid infiltration. However, validation of its prognostic value in larger series is required before its introduction into routine practice for prognostic evaluation in patients with colorectal carcinomas. Virtual slides: The virtual slide(s) for this article can be found here:http://www.diagnosticpathology.diagnomx.eu/vs/9861460717895880